Literature DB >> 19681829

Pulmonary zygomycosis in solid organ transplant recipients in the current era.

H-Y Sun1, J M Aguado, H Bonatti, G Forrest, K L Gupta, N Safdar, G T John, K J Pursell, P Muñoz, R Patel, J Fortun, P Martin-Davila, B Philippe, F Philit, A Tabah, N Terzi, V Chatelet, S Kusne, N Clark, E Blumberg, M B Julia, A Humar, S Houston, C Lass-Florl, L Johnson, E R Dubberke, M A Barron, O Lortholary, N Singh.   

Abstract

Fifty-eight solid organ transplant recipients with zygomycosis were studied to assess the presentation, radiographic characteristics, risks for extra-pulmonary dissemination and mortality of pulmonary zygomycosis. Pulmonary zygomycosis was documented in 31 patients (53%) and developed a median of 5.5 months (interquartile range, 2-11 months) posttransplantation. In all, 74.2% (23/31) of the patients had zygomycosis limited to the lungs and 25.8% (8/31) had lung disease as part of disseminated zygomycosis; cutaneous/soft tissue (50%, 4/8) was the most common site of dissemination. Pulmonary disease presented most frequently as consolidation/mass lesions (29.0%), nodules (25.8%) and cavities (22.6%). Patients with disseminated disease were more likely to have Mycocladus corymbifer as the causative pathogen. The mortality rate at 90 days after the treatment was 45.2%. In summary, pulmonary zygomycosis is the most common manifestation in solid organ transplant recipients with zygomycosis, and disseminated disease often involves the cutaneous/soft tissue sites but not the brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681829     DOI: 10.1111/j.1600-6143.2009.02754.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  20 in total

1.  Wound infection caused by Lichtheimia ramosa due to a car accident.

Authors:  Evangelia Bibashi; G Sybren de Hoog; Theodoros E Pavlidis; Nikolaos Symeonidis; Athanasios Sakantamis; Grit Walther
Journal:  Med Mycol Case Rep       Date:  2012-12-08

Review 2.  Infections after lung transplantation.

Authors:  Mario Nosotti; Paolo Tarsia; Letizia Corinna Morlacchi
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  Future directions in mucormycosis research.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis; Oliver Lortholary; Oliver Lotholary; Brad Spellberg; Georgios Petrikkos; Emmanuel Roilides; Emmanuel Roillides; Ashraf Ibrahim; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 4.  Human Fungal Pathogens of Mucorales and Entomophthorales.

Authors:  Leonel Mendoza; Raquel Vilela; Kerstin Voelz; Ashraf S Ibrahim; Kerstin Voigt; Soo Chan Lee
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

5.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

Review 6.  Emerging fungal infections in solid organ transplant recipients.

Authors:  Shmuel Shoham
Journal:  Infect Dis Clin North Am       Date:  2013-04-17       Impact factor: 5.982

Review 7.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

8.  Primary cutaneous mucormycosis in a patient with burn wounds due to Lichtheimia ramosa.

Authors:  Ravinder Kaur; Kiran Bala; Rajeev B Ahuja; Prabhat Srivastav; Umesh Bansal
Journal:  Mycopathologia       Date:  2014-08-29       Impact factor: 2.574

Review 9.  Invasive fungal infections in solid organ transplant recipients.

Authors:  Shmuel Shoham; Kieren A Marr
Journal:  Future Microbiol       Date:  2012-05       Impact factor: 3.165

10.  Zygomycosis in Immunocompromised non-Haematological Patients.

Authors:  George Petrikkos; Miranda Drogari-Apiranthitou
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-03-15       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.